Newsletter Subscription

Enter Name and Email

17 October 2014 - Adrian to chair session and present at World Orphan Drug Congress

Adrian Newman-Tancredi will be chairing a session at the World Orphan Drug Congress in Brussels, Belgium, on 12th to 14th October 2014. Dr. Newman-Tancredi has been invited to chair the session on "Innovation in the Orphan Drug Sector". In addition, Dr. Newman-Tancredi will also give a joint presentation with Dr. Ana Paula Abdala Sheikh of Bristol University, entitled "Targeting Rett syndrome with NLX-101, a novel Orphan Medicinal Product".

In his capacity as Chief Scientific Officer of Neurolixis, a biotechnology company, Dr. Newman-Tancredi is participating in the developmzent of the clinical candidate, NLX-101, as a treatment for Rett syndrome, a serious orphan disorder that affects about 30 000 girls in Europe and North America. Investigation of the physiological effects of NLX-101 is being conducted by Dr. Abdala Sheik at the University of Bristol in the laboratory of Prof. Julian Paton with support from the International Rett Syndrome Foundation and the Rett Syndrome Research Trust (see previous press release).

For full details of the World Orphan Drug Congress program see the meeting website.

Adrian has extensive experience of neuropsychiatric drug discovery and has presented to a wide variety of audiences. If you would like more information: Contact.